Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3731
Abstract: Blinatumomab is a BiTE® immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). read more here.
Keywords: relapsed refractory; lymphoblastic leukemia; blinatumomab; cell precursor ... See more keywords
Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02771-2
Abstract: Tisagenlecleucel is an autologous T cell genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor. Here, we present the efficacy and safety of tisagenlecleucel in a subgroup of Japanese patients… read more here.
Keywords: relapsed refractory; efficacy safety; refractory cell; safety tisagenlecleucel ... See more keywords
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Drug Safety"
DOI: 10.1007/s40264-018-0760-1
Abstract: Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive… read more here.
Keywords: relapsed refractory; blinatumomab treatment; cell precursor; refractory cell ... See more keywords
Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15308
Abstract: Parsaclisib, a potent, selective, next‐generation PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory B‐cell lymphoma. We undertook a phase Ib study (CITADEL‐111) evaluating safety, pharmacokinetics, and efficacy of parsaclisib in Japanese… read more here.
Keywords: cell lymphoma; relapsed refractory; japanese patients; refractory cell ... See more keywords
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1047
Abstract: Purpose: Preclinical studies suggest SYK and JAK contribute to tumor-intrinsic and microenvironment-derived survival signals. The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investigated. Patients and Methods: In a phase… read more here.
Keywords: relapsed refractory; response; syk jak; refractory cell ... See more keywords
IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134607
Abstract: Introduction Part B of the modified Magrath regimen (ifosfamide, etoposide, and cytarabine; IVAC) with or without rituximab (R) is utilized as a standalone regimen in the management of relapsed/refractory Burkitt lymphoma and other non-Hodgkin lymphomas… read more here.
Keywords: refractory cell; ivac; patients received; cell ... See more keywords
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005579
Abstract: Key Points Blinatumomab was associated with low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%). The best blinatumomab outcomes were seen in patients… read more here.
Keywords: blinatumomab pediatric; refractory cell; cell acute; pediatric relapsed ... See more keywords
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006631
Abstract: Key Points One intravenous dose of oncolytic VSV has single-agent activity in patients with relapsed refractory T-cell lymphoma. Direct oncolytic tumor cell killing and subsequent immune cell activation were observed, resulting in durable remissions in… read more here.
Keywords: cell; oncolytic vsv; cell lymphoma; relapsed refractory ... See more keywords
Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3044
Abstract: 3044Background: Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, contains a murine single chain variable fragment (mCAR19) binding domain. Humoral immunity to anti-mCAR19 had no ... read more here.
Keywords: relapsed refractory; cell acute; tisagenlecleucel relapsed; refractory cell ... See more keywords
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
Sign Up to like & getrecommendations! Published in 2022 at "Haematologica"
DOI: 10.3324/haematol.2022.280900
Abstract: Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally… read more here.
Keywords: hodgkin lymphoma; non hodgkin; lymphoma; refractory cell ... See more keywords
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.564099
Abstract: Background The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from… read more here.
Keywords: relapsed refractory; generation; refractory cell; cell ... See more keywords